Company profile: PepGen
1.1 - Company Overview
Company description
- Provider of an Enhanced Delivery Oligonucleotide (EDO) platform to improve delivery and efficacy of oligonucleotide therapies, focusing on antisense oligonucleotides for neuromuscular and neurological disorders, and therapy candidates including PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) and PGN-EDO51 for Duchenne Muscular Dystrophy (DMD).
Products and services
- Enhanced Delivery Oligonucleotide (EDO) platform: PepGen engineers a custom-engineered platform improving delivery and efficacy of oligonucleotide therapeutics, including antisense oligonucleotides, for neuromuscular and neurological disorders via optimized tissue targeting and activity
- PGN-EDO51: PepGen builds a muscle-targeted therapy candidate for Duchenne Muscular Dystrophy that enhances delivery to muscle tissues using the EDO platform, boosting activity
- PGN-EDODM1: PepGen develops an indication-specific therapy candidate for Myotonic Dystrophy Type 1 leveraging the EDO platform to improve oligonucleotide delivery and activity in disease-relevant tissues
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to PepGen
HRA Pharma
HQ: France
Website
- Description: Provider of drugs, devices, and services in reproductive health and endocrine diseases, offering products such as Norlevo for emergency contraception; Cicatridine for vaginitis and vaginal injury; Delidose, Divina, and Duova for hormone replacement therapy; and GyMiso for cervical ripening.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HRA Pharma company profile →
Synaptogenix
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies in development for neurodegenerative diseases, using bryostatin to promote neuronal health and synaptic regeneration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synaptogenix company profile →
Tolmar
HQ: United States
Website
- Description: Provider of pharmaceutical research, development, manufacturing and commercial operations, delivering proprietary and generic products in dermatology, oncology, and dental therapeutics, including ELIGARD (leuprolide acetate for prostate cancer), Fensolvi (leuprolide acetate for central precocious puberty), and topical dermatology generics—ointments, creams, gels, and lotions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tolmar company profile →
Retrophin
HQ: United States
Website
- Description: Provider of therapies and programs for rare diseases, including FILSPARI (sparsentan) for adults with IgA nephropathy; a late-stage therapy for focal segmental glomerulosclerosis; a potential disease-modifying therapy for classical homocystinuria; preclinical Alagille syndrome research with NIH and ALGSA; and support for newborn screening modernization and a telehealth model to improve specialist access.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Retrophin company profile →
Adnexus Therapeutics
HQ: United States
Website
- Description: Provider of discovery and development of Adnectins, a novel proprietary class of targeted biologics designed to block or stimulate therapeutic targets to fight diseases across a broad range of therapeutic areas; operates as a Bristol-Myers Squibb R&D company in the United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adnexus Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for PepGen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to PepGen
2.2 - Growth funds investing in similar companies to PepGen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for PepGen
4.2 - Public trading comparable groups for PepGen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →